Introduction Bladder cancer is a common malignancy that is an expensive cancer to treat [1]. In England, over 18,000 people are diagnosed with bladder cancer every year, of which approximately 25% are muscle-invasive bladder cancers (MIBCs) [2]. MIBC has a 50% 5-year survival rate despite radical surgery, radiotherapy and chemotherapy [3]. Cisplatin-based neoadjuvant chemotherapy (NAC) is standard of care for MIBC and is associated with a 5% absolute increase in survival rate [4, 5].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Paul
Contact Paul, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack